冠状动脉疾病(CAD)市场:规模，全球市场的预测(2023年～2028年)，产业趋势，成长，占有率，预测，通货膨胀的影响，企业的机会分析

全球冠状动脉疾病(CAD)的市场规模在2022年估算为229亿4,000万美金，2028年将达到381亿7,000万美元。2022年～2028年预计将以年复合成长率8.86％的速度成长。

本报告提供全球冠状动脉疾病(CAD)市场相关调查，提供市场概要，以及各国，各药物类型，各流通管道趋势，及加入此市场的主要企业简介等资讯。

目录

第1章 简介

第2章 调查和调查手法

第3章 摘要整理

第4章 市场动态

• 促进因素
• 课题

第5章 SWOT分析-冠状动脉疾病市场

第6章 波特的五力分析

第7章 市场冠状动脉疾病市场-主要8个国家

第8章 市场占有率- 冠状动脉疾病的分析

• 市场各国(主要8个国家)
• 各药物类型
• 各流通管道

第9章 冠状动脉疾病市场，各国

• 美国
• 法国
• 德国
• 中国
• 英国
• 日本
• 沙乌地阿拉伯
• 俄罗斯

第10章 冠状动脉疾病市场，各药物类型

• 抗血小板
• β受体阻断剂
• 钙拮抗剂
• 抗凝固剂
• 其他

第11章 冠状动脉疾病市场，各流通管道

• 院内药局
• 零售药局
• 线上药局

第12章 临床试验药-冠状动脉疾病

• 秋水仙碱
• Rivaroxaban2.5mg口服锁

第13章 主要加入企业的分析

• AstraZeneca Plc
• Novartis AG
• Pfizer Inc
• Bristol-Myers Squibb Company
• Merck & Co., Inc
• Viatris
• Sanofi
• Amgen

Coronary Artery Disease (CAD) Market will reach US$ 38.17 Billion in 2028, according to Renub Research. Coronary artery disease (CAD) is a major public health concern worldwide, and its prevalence has been increasing over the years. Coronary artery disease (CAD) is the narrowing or blockage of coronary arteries, which supply oxygen-rich blood to the heart; this happens due to the accumulation of fatty deposits called plaques, which can cause chest pain (angina), shortness of breath, and other symptoms by reducing the blood flow to the heart.

In severe cases, CAD can lead to a heart attack or other complications. The risk factors for CAD include high blood pressure, high cholesterol, smoking, obesity, diabetes, and a family history of the disease. Treating CAD is possible with lifestyle changes, medications, or procedures like angioplasty or bypass surgery to improve blood flow to the heart. The National Center for Biotechnology Information (NCBI) 2023 report states that coronary artery disease (CAD) is responsible for 17.8 million deaths yearly, making it the third leading cause of mortality worldwide.

Coronary Artery Disease (CAD) Market shall grow at a CAGR of 8.86% from 2022 to 2028

The increasing prevalence of CAD due to aging populations, unhealthy lifestyles, and rising rates of obesity and diabetes is driving growth in the coronary artery disease market. Therefore, there is a rising need for diagnostic tools and treatments, such as medication, medical devices, and surgical procedures. Furthermore, advances in medical technology and research have also led to new and more effective therapies for CAD, including drug-eluting stents and minimally invasive procedures. In addition, tailoring treatment plans to individual patients based on their unique factors is becoming increasingly popular, known as personalized medicine. Hence, the coronary artery disease (CAD) market was US$ 22.94 Billion in 2022.

Anti-platelet Drugs have hegemony in the Coronary Artery Disease (CAD) Market

Drug types in the coronary artery disease (CAD) market are antiplatelets, beta-blockers, calcium antagonists, anticoagulants, and others. Antiplatelet drugs are the dominant therapy in the coronary artery disease market, as they are widely used to prevent blood clots that can lead to heart attacks and strokes in patients with CAD. In addition, they have been proven effective in reducing the risk of recurrent cardiovascular events and have a low risk of side effects, making them a safe long-term option for CAD patients. To manage CAD, use antiplatelet drugs in combination with other therapies such as statins, beta-blockers, and ACE inhibitors.

Anticoagulant drugs for coronary artery disease have grown due to various factors. They prevent blood clots in CAD patients, the development of newer medications like DOACs, the increasing prevalence of CAD, and the demand for effective anticoagulant therapies. Personalized medicine has also contributed to growth, as tailored treatment plans can optimize drug use and improve patient outcomes.

Increasing demand for Medications has led to the Growth of Retail Pharmacies in the Coronary Artery Disease Market

The coronary artery disease (CAD) market has hospital pharmacies, retail pharmacies, and online pharmacies distribution channels mainly. The growth of retail pharmacies in the coronary artery disease market is due to the increasing demand for medications used in CAD treatment and management, the aging population, and technological advancements. These have expanded retail pharmacies' product offerings and services, making them a more attractive option for patients seeking comprehensive healthcare services. In addition, changes in healthcare policy and reimbursement models have also incentivized patients to seek care in retail pharmacies.

However, hospital pharmacies are an authority in the coronary artery disease (CAD) market as they are often the first point of contact for CAD patients, particularly those with acute conditions. They have access to a broader range of medications and specialized products and highly trained professionals with expertise in CAD management. In addition, the trend toward value-based healthcare has led to the development of integrated healthcare systems, making hospital pharmacies integral in providing various services in a single location.

China Coronary Artery Disease (CAD) Market has grown because of an aging population and the growing prevalence of chronic ailments like obesity and diabetes. U.S., France, Germany, China, United Kingdom, Japan, Saudi Arabia, and Russia are the countries that comprise the coronary artery disease (CAD) market.

Expanding China's healthcare system and investing in medical infrastructure have improved CAD treatment and management. Furthermore, the rise of China's middle class has created opportunities for foreign and domestic pharmaceutical companies to enter the Chinese coronary artery disease (CAD) market. In addition, the government's focus on promoting innovation and research in healthcare has led to new CAD therapies and management strategies, including TCM. Finally, policies promoting healthy lifestyles and disease management programs have contributed to the coronary artery disease (CAD) market growth.

The US dominates the CAD market due to its high prevalence of risk factors for CAD, resulting in a significant need for CAD treatments. CAD is the main reason for mortality in the US. The National Centre of Biotechnology Information (NCBI) report of 2023 states that coronary artery disease (CAD) is responsible for approximately 610,000 deaths annually accounting for an estimated 1 in 4 deaths in the United States, making it the leading cause of mortality. The country also has advanced medical infrastructure, leading pharmaceutical and medical device companies, and heavy investment in healthcare research and development. Moreover, the US prioritizes preventive healthcare, focusing more on CAD prevention and management.

Key Players

AstraZeneca Plc., Novartis AG, Pfizer Inc, Bristol-Myers Squibb Company, Merck & Co. Inc, Viatris, Sanofi, and Amgen are prominent in the coronary artery disease (CAD) market.

In May 2022: The use of the brand name Bemdac by Zydus Lifesciences to introduce bempedoic acid, an oral medication for lipid-lowering that does not belong to the statin class, for the treatment of cardiovascular diseases in India.

In May 2022: Amgen announced positive topline results from the Phase 2 clinical trial of olpasiran in adult patients with evidence of atherosclerotic cardiovascular disease (ASCVD) and Lipoprotein(a).

Renub Research report titled "Coronary Artery Disease (CAD) Market Global Forecast by Drug Types (antiplatelets, beta-blockers, calcium antagonists, anticoagulants, and others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Countries (U.S., France, Germany, China, United Kingdom, Japan, Saudi Arabia, and Russia), Clinical Trial Drugs (Colchicine, Rivaroxaban 2.5 Mg Oral Tablet), Company Analysis (AstraZeneca Plc., Novartis AG, Pfizer Inc, Bristol-Myers Squibb Company, Merck & Co. Inc, Viatris, Sanofi, and Amgen)" provides a detailed analysis of Coronary Artery Disease (CAD) Market.

Drug Types- Market breakup from 5 Viewpoints:

1. Antiplatelets

2. beta-blockers

3. calcium antagonists

4. anticoagulants

5. others

Distribution channels- Market breakup from 3 Viewpoints:

1. Hospital pharmacies

2. Retail pharmacies

3. Online pharmacies

Countries- Market breakup from 8 Viewpoints:

1. United States

2. France

3. Germany

4. China

5. United Kingdom

6. Japan

7. Saudi Arabia

8. Russia

Clinical Trial Drugs- Overview for 2 Drugs

1. Colchicine

2. Rivaroxaban 2.5 Mg Oral Tablet

The company has been covered from 3 Viewpoints:

• Overview
• Recent Development
• Revenue

Company Analysis:

1. AstraZeneca Plc.

2. Novartis AG

3. Pfizer Inc

4. Bristol-Myers Squibb Company

5. Merck & Co. Inc

6. Viatris

7. Sanofi

8. Amgen

Table of Contents

1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market Dynamics

• 4.1 Growth Drivers
• 4.2 Challenges

5. SWOT Analysis-Coronary Artery Disease Market

• 5.1 Strength
• 5.2 Weakness
• 5.3 Opportunity
• 5.4 Threat

6. Porter's Five Forces

• 6.1 Bargaining Power of Buyers
• 6.2 Bargaining Power of Suppliers
• 6.3 Degree of Competition
• 6.4 Threat of New Entrants
• 6.5 Threat of Substitutes

7. Coronary Artery Disease Market-8MM

8. Market Share - Coronary Artery Disease Analysis

• 8.1 By Country (8 Major Markets)
• 8.2 By Drug Type
• 8.3 By Distribution Channel

9. Country - Coronary Artery Disease Market

• 9.1 United States
  • 9.1.1 Prevalence Rate
  • 9.1.2 Population
    • 9.1.2.1 Coronary Artery Disease Population
    • 9.1.2.2 Physician Visiting - CAD Population
  • 9.1.3 Price Analysis
  • 9.1.4 CAD Mortality Analysis
  • 9.1.5 Market
• 9.2 France
  • 9.2.1 Prevalence Rate
  • 9.2.2 Population
    • 9.2.2.1 Coronary Artery Disease Population
    • 9.2.2.2 Physician Visiting - CAD Population
  • 9.2.3 Price Analysis
  • 9.2.4 CAD Mortality Analysis
  • 9.2.5 Market
• 9.3 Germany
  • 9.3.1 Prevalence Rate
  • 9.3.2 Population
    • 9.3.2.1 Coronary Artery Disease Population
    • 9.3.2.2 Physician Visiting - CAD Population
  • 9.3.3 Price Analysis
  • 9.3.4 CAD Mortality Analysis
  • 9.3.5 Market
• 9.4 China
  • 9.4.1 Prevalence Rate
  • 9.4.2 Population
    • 9.4.2.1 Coronary Artery Disease Population
    • 9.4.2.2 Physician Visiting - CAD Population
  • 9.4.3 Price Analysis
  • 9.4.4 CAD Mortality Analysis
  • 9.4.5 Market
• 9.5 United Kingdom
  • 9.5.1 Prevalence Rate
  • 9.5.2 Population
    • 9.5.2.1 Coronary Artery Disease Population
    • 9.5.2.2 Physician Visiting - CAD Population
  • 9.5.3 Price Analysis
  • 9.5.4 CAD Mortality Analysis
  • 9.5.5 Market
• 9.6 Japan
  • 9.6.1 Prevalence Rate
  • 9.6.2 Population
    • 9.6.2.1 Coronary Artery Disease Population
    • 9.6.2.2 Physician Visiting - CAD Population
  • 9.6.3 Price Analysis
  • 9.6.4 CAD Mortality Analysis
  • 9.6.5 Market
• 9.7 Saudi Arabia
  • 9.7.1 Prevalence Rate
  • 9.7.2 Population
    • 9.7.2.1 Coronary Artery Disease Population
    • 9.7.2.2 Physician Visiting - CAD Population
  • 9.7.3 Price Analysis
  • 9.7.4 CAD Mortality Analysis
  • 9.7.5 Market
• 9.8 Russia
  • 9.8.1 Prevalence Rate
  • 9.8.2 Population
    • 9.8.2.1 Coronary Artery Disease Population
    • 9.8.2.2 Physician Visiting - CAD Population
  • 9.8.3 Price Analysis
  • 9.8.4 CAD Mortality Analysis
  • 9.8.5 Market

10. Drug Type-Coronary Artery Disease Market

• 10.1 Anti Platelets
• 10.2 Beta Blockers
• 10.3 Calcium Antagonists
• 10.4 Anticoagulants
• 10.5 Others

11. Distribution Channel- Coronary Artery Disease Market

• 11.1 Hospital Pharmacies
• 11.2 Retail Pharmacies
• 11.3 Online Pharmacies

12. Clinical Trials Drugs-Coronary Artery Disease

• 12.1 Colchicine
• 12.2 Rivaroxaban 2.5 Mg Oral Tablet

13. Key Players Analysis

• 13.1 AstraZeneca Plc
  • 13.1.1 Company overview
  • 13.1.2 Sales Analysis
  • 13.1.3 Recent Development
• 13.2 Novartis AG
  • 13.2.1 Company overview
  • 13.2.2 Sales Analysis
  • 13.2.3 Recent Development
• 13.3 Pfizer Inc.
  • 13.3.1 Company overview
  • 13.3.2 Sales Analysis
  • 13.3.3 Recent Development
• 13.4 Bristol-Myers Squibb Company
  • 13.4.1 Company overview
  • 13.4.2 Sales Analysis
  • 13.4.3 Recent Development
• 13.5 Merck & Co., Inc
  • 13.5.1 Company overview
  • 13.5.2 Sales Analysis
  • 13.5.3 Recent Development
• 13.6 Viatris
  • 13.6.1 Company overview
  • 13.6.2 Sales Analysis
  • 13.6.3 Recent Development
• 13.7 Sanofi
  • 13.7.1 Company overview
  • 13.7.2 Sales Analysis
  • 13.7.3 Recent Development
• 13.8 Amgen
  • 13.8.1 Company overview
  • 13.8.2 Sales Analysis
  • 13.8.3 Recent Development

List of Figures

• Figure-01: Global - Coronary Artery Disease Market (Billion US$), 2018 - 2022
• Figure-02: Global - Forecast for Coronary Artery Disease Market (Billion US$), 2023 - 2028
• Figure-03: United States - Prevalence Rate (Percent), 2018 - 2022
• Figure-04: United States - Forecast for Prevalence Rate (Percent), 2023 - 2028
• Figure-05: United States - Coronary Artery Disease Population (Number), 2018 - 2022
• Figure-06: United States - Forecast for Coronary Artery Disease Population (Number), 2023 - 2028
• Figure-07: United States - Physician Visiting - CAD Population (Number), 2018 - 2022
• Figure-08: United States - Forecast for Physician Visiting - CAD Population (Number), 2023 - 2028
• Figure-09: United States - Price Analysis (US$), 2018 - 2022
• Figure-10: United States - Forecast for Price Analysis (US$), 2023 - 2028
• Figure-11: United States - CAD Mortality (Number), 2018 - 2022
• Figure-12: United States - Forecast for CAD Mortality (Number), 2023 - 2028
• Figure-13: United States - Coronary Artery Disease Market (Million US$), 2018 - 2022
• Figure-14: United States - Forecast for Coronary Artery Disease Market (Million US$), 2023 - 2028
• Figure-15: France - Prevalence Rate (Percent), 2018 - 2022
• Figure-16: France - Forecast for Prevalence Rate (Percent), 2023 - 2028
• Figure-17: France - Coronary Artery Disease Population (Number), 2018 - 2022
• Figure-18: France - Forecast for Coronary Artery Disease Population (Number), 2023 - 2028
• Figure-19: France - Physician Visiting - CAD Population (Number), 2018 - 2022
• Figure-20: France - Forecast for Physician Visiting - CAD Population (Number), 2023 - 2028
• Figure-21: France - Price Analysis (US$), 2018 - 2022
• Figure-22: France - Forecast for Price Analysis (US$), 2023 - 2028
• Figure-23: France - CAD Mortality (Number), 2018 - 2022
• Figure-24: France - Forecast for CAD Mortality (Number), 2023 - 2028
• Figure-25: France - Coronary Artery Disease Market (Million US$), 2018 - 2022
• Figure-26: France - Forecast for Coronary Artery Disease Market (Million US$), 2023 - 2028
• Figure-27: Germany - Prevalence Rate (Percent), 2018 - 2022
• Figure-28: Germany - Forecast for Prevalence Rate (Percent), 2023 - 2028
• Figure-29: Germany - Coronary Artery Disease Population (Number), 2018 - 2022
• Figure-30: Germany - Forecast for Coronary Artery Disease Population (Number), 2023 - 2028
• Figure-31: Germany - Physician Visiting - CAD Population (Number), 2018 - 2022
• Figure-32: Germany - Forecast for Physician Visiting - CAD Population (Number), 2023 - 2028
• Figure-33: Germany - Price Analysis (US$), 2018 - 2022
• Figure-34: Germany - Forecast for Price Analysis (US$), 2023 - 2028
• Figure-35: Germany - CAD Mortality (Number), 2018 - 2022
• Figure-36: Germany - Forecast for CAD Mortality (Number), 2023 - 2028
• Figure-37: Germany - Coronary Artery Disease Market (Million US$), 2018 - 2022
• Figure-38: Germany - Forecast for Coronary Artery Disease Market (Million US$), 2023 - 2028
• Figure-39: China - Prevalence Rate (Percent), 2018 - 2022
• Figure-40: China - Forecast for Prevalence Rate (Percent), 2023 - 2028
• Figure-41: China - Coronary Artery Disease Population (Number), 2018 - 2022
• Figure-42: China - Forecast for Coronary Artery Disease Population (Number), 2023 - 2028
• Figure-43: China - Physician Visiting - CAD Population (Number), 2018 - 2022
• Figure-44: China - Forecast for Physician Visiting - CAD Population (Number), 2023 - 2028
• Figure-45: China - Price Analysis (US$), 2018 - 2022
• Figure-46: China - Forecast for Price Analysis (US$), 2023 - 2028
• Figure-47: China - CAD Mortality (Number), 2018 - 2022
• Figure-48: China - Forecast for CAD Mortality (Number), 2023 - 2028
• Figure-49: China - Coronary Artery Disease Market (Million US$), 2018 - 2022
• Figure-50: China - Forecast for Coronary Artery Disease Market (Million US$), 2023 - 2028
• Figure-51: United Kingdom - Prevalence Rate (Percent), 2018 - 2022
• Figure-52: United Kingdom - Forecast for Prevalence Rate (Percent), 2023 - 2028
• Figure-53: United Kingdom - Coronary Artery Disease Population (Number), 2018 - 2022
• Figure-54: United Kingdom - Forecast for Coronary Artery Disease Population (Number), 2023 - 2028
• Figure-55: United Kingdom - Physician Visiting - CAD Population (Number), 2018 - 2022
• Figure-56: United Kingdom - Forecast for Physician Visiting - CAD Population (Number), 2023 - 2028
• Figure-57: United Kingdom - Price Analysis (US$), 2018 - 2022
• Figure-58: United Kingdom - Forecast for Price Analysis (US$), 2023 - 2028
• Figure-59: United Kingdom - CAD Mortality (Number), 2018 - 2022
• Figure-60: United Kingdom - Forecast for CAD Mortality (Number), 2023 - 2028
• Figure-61: United Kingdom - Coronary Artery Disease Market (Million US$), 2018 - 2022
• Figure-62: United Kingdom - Forecast for Coronary Artery Disease Market (Million US$), 2023 - 2028
• Figure-63: Japan - Prevalence Rate (Percent), 2018 - 2022
• Figure-64: Japan - Forecast for Prevalence Rate (Percent), 2023 - 2028
• Figure-65: Japan - Coronary Artery Disease Population (Number), 2018 - 2022
• Figure-66: Japan - Forecast for Coronary Artery Disease Population (Number), 2023 - 2028
• Figure-67: Japan - Physician Visiting - CAD Population (Number), 2018 - 2022
• Figure-68: Japan - Forecast for Physician Visiting - CAD Population (Number), 2023 - 2028
• Figure-69: Japan - Price Analysis (US$), 2018 - 2022
• Figure-70: Japan - Forecast for Price Analysis (US$), 2023 - 2028
• Figure-71: Japan - CAD Mortality (Number), 2018 - 2022
• Figure-72: Japan - Forecast for CAD Mortality (Number), 2023 - 2028
• Figure-73: Japan - Coronary Artery Disease Market (Million US$), 2018 - 2022
• Figure-74: Japan - Forecast for Coronary Artery Disease Market (Million US$), 2023 - 2028
• Figure-75: Saudi Arabia - Prevalence Rate (Percent), 2018 - 2022
• Figure-76: Saudi Arabia - Forecast for Prevalence Rate (Percent), 2023 - 2028
• Figure-77: Saudi Arabia - Coronary Artery Disease Population (Number), 2018 - 2022
• Figure-78: Saudi Arabia - Forecast for Coronary Artery Disease Population (Number), 2023 - 2028
• Figure-79: Saudi Arabia - Physician Visiting - CAD Population (Number), 2018 - 2022
• Figure-80: Saudi Arabia - Forecast for Physician Visiting - CAD Population (Number), 2023 - 2028
• Figure-81: Saudi Arabia - Price Analysis (US$), 2018 - 2022
• Figure-82: Saudi Arabia - Forecast for Price Analysis (US$), 2023 - 2028
• Figure-83: Saudi Arabia - CAD Mortality (Number), 2018 - 2022
• Figure-84: Saudi Arabia - Forecast for CAD Mortality (Number), 2023 - 2028
• Figure-85: Saudi Arabia - Coronary Artery Disease Market (Million US$), 2018 - 2022
• Figure-86: Saudi Arabia - Forecast for Coronary Artery Disease Market (Million US$), 2023 - 2028
• Figure-87: Russia - Prevalence Rate (Percent), 2018 - 2022
• Figure-88: Russia - Forecast for Prevalence Rate (Percent), 2023 - 2028
• Figure-89: Russia - Coronary Artery Disease Population (Number), 2018 - 2022
• Figure-90: Russia - Forecast for Coronary Artery Disease Population (Number), 2023 - 2028
• Figure-91: Russia - Physician Visiting - CAD Population (Number), 2018 - 2022
• Figure-92: Russia - Forecast for Physician Visiting - CAD Population (Number), 2023 - 2028
• Figure-93: Russia - Price Analysis (US$), 2018 - 2022
• Figure-94: Russia - Forecast for Price Analysis (US$), 2023 - 2028
• Figure-95: Russia - CAD Mortality (Number), 2018 - 2022
• Figure-96: Russia - Forecast for CAD Mortality (Number), 2023 - 2028
• Figure-97: Russia - Coronary Artery Disease Market (Million US$), 2018 - 2022
• Figure-98: Russia - Forecast for Coronary Artery Disease Market (Million US$), 2023 - 2028
• Figure-99: Drug Type - Anti Platelets (Percent), 2018 - 2022
• Figure-100: Drug Type - Forecast for Anti Platelets (Percent), 2023 - 2028
• Figure-101: Drug Type - Beta Blockers (Number), 2018 - 2022
• Figure-102: Drug Type - Forecast for Beta Blockers (Number), 2023 - 2028
• Figure-103: Drug Type - Calcium Antagonists (Number), 2018 - 2022
• Figure-104: Drug Type - Forecast for Calcium Antagonists (Number), 2023 - 2028
• Figure-105: Drug Type - Anticoagulants (US$), 2018 - 2022
• Figure-106: Drug Type - Forecast for Anticoagulants (US$), 2023 - 2028
• Figure-107: Drug Type - Others (Number), 2018 - 2022
• Figure-108: Drug Type - Forecast for Others (Number), 2023 - 2028
• Figure-109: Distribution Channel - Hospital Pharmacies Market (Million US$), 2018 - 2022
• Figure-110: Distribution Channel - Forecast for Hospital Pharmacies Market (Million US$), 2023 - 2028
• Figure-111: Distribution Channel - Retail Pharmacies Market (Million US$), 2018 - 2022
• Figure-112: Distribution Channel - Forecast for Retail Pharmacies Market (Million US$), 2023 - 2028
• Figure-113: Distribution Channel - Online Pharmacies Market (Million US$), 2018 - 2022
• Figure-114: Distribution Channel - Forecast for Online Pharmacies Market (Million US$), 2023 - 2028
• Figure-115: AstraZeneca Plc - Global Revenue (Billion US$), 2018 - 2022
• Figure-116: AstraZeneca Plc - Forecast for Global Revenue (Billion US$), 2023 - 2028
• Figure-117: Novartis AG - Global Revenue (Billion US$), 2018 - 2022
• Figure-118: Novartis AG - Forecast for Global Revenue (Billion US$), 2023 - 2028
• Figure-119: Pfizer Inc. - Global Revenue (Billion US$), 2018 - 2022
• Figure-120: Pfizer Inc. - Forecast for Global Revenue (Billion US$), 2023 - 2028
• Figure-121: Bristol-Myers Squibb Company - Global Revenue (Million US$), 2018 - 2022
• Figure-122: Bristol-Myers Squibb Company - Forecast for Global Revenue (Million US$), 2023 - 2028
• Figure-123: Merck & Co., Inc - Global Revenue (Billion US$), 2018 - 2022
• Figure-124: Merck & Co., Inc - Forecast for Global Revenue (Billion US$), 2023 - 2028
• Figure-125: Viatris - Global Revenue (Billion US$), 2018 - 2022
• Figure-126: Viatris - Forecast for Global Revenue (Billion US$), 2023 - 2028
• Figure-127: Sanofi - Global Revenue (Billion US$), 2018 - 2022
• Figure-128: Sanofi - Forecast for Global Revenue (Billion US$), 2023 - 2028
• Figure-129: Amgen - Global Revenue (Billion US$), 2018 - 2022
• Figure-130: Amgen - Forecast for Global Revenue (Billion US$), 2023 - 2028

List of Tables

• Table-01: Global - Coronary Artery Disease Market Share by Country (Percent), 2018 - 2022
• Table-02: Global - Forecast for Coronary Artery Disease Market Share by Country (Percent), 2023 - 2028
• Table-03: Global - Coronary Artery Disease Market Share by Drug Type (Percent), 2018 - 2022
• Table-04: Global - Forecast for Coronary Artery Disease Market Share by Drug Type (Percent), 2023 - 2028
• Table-05: Global - Coronary Artery Disease Market Share by Distribution Channel (Percent), 2018 - 2022
• Table-06: Global - Forecast for Coronary Artery Disease Market Share by Distribution Channel (Percent), 2023 - 2028